Intercontinental cooperative non-Hodgkin T cell lymphoma prospective registry study

Abstract

Background: T cell lymphomas are a relatively rare and heterogeneous group of disease. Because of its rarity and diversity, most published data have been based on small, and single-center retrospective studies. Method(s): Here, we conducted a multi-center, prospective registry study of non-Hodgkin T cell lymphoma. From April 2016 to Dec 2016, a total of 85 patients who were diagnosed as mature Tcell non-Hodgkin lymphoma based on the World Health Organization Classification 2008 were enrolled (Korea, n = 59; China, n = 13; Taiwan, n= 8; Indonesia, n = 4; Singapore, n = 1). Among them, data from 49 patients were used in this interim analysis. Result(s): The median age was 56 years. Among the patients enrolled, extranodal NK T cell lymphoma was the most common diseaseaccounting for 34.7%(n=17), and AITL (24.5%, n=12), PTCL (22.4%, n=11), ALCL (10.2%, n=5), EATL (4.1%, n=2), Cutaneous Tcell lymphoma (2.0%, n=1), and T-LBL were followed (2.0%, n=1). CHOP based regimen was most commonly used as1st line treatment, which comprised 75% of all regimens used except in the case of extranodal NK T cell lym-phoma. Except patients whose treatment response to 1st line therapy was unknown (n = 10) or not evaluable (n = 6), complete response, partial response, stable disease and progressive disease were reported in 17 (51.5%), 3 (9.1%), 3 (9.1%) and 10 patients (30.3%). Overall, 10 patients proceeded autologous transplantation (20.4%), and 7 of whom underwent transplantation as an upfront treatment. Median overall survival was not reached due to a short period of follow up (median 6.6 months). Conclusion(s): This study shows interim results of clinical response and patient outcome of non-Hodgkin T cell lymphoma in real world treatment practice. The study is still ongoing, and further data collection is needed to provide information useful for establishing effective treatment strategies.